glp 1 agonist eli lilly The GLP-1 market is projected to exceed 100B USD by 2030 Eli Lilly's oral GLP-1 pill

(8) Obesity and bone have both a mechanical and metabolic relationship

As with many of the options on this list, it is not FDA-approved for use as a weight loss medication

The potential for creating or exacerbating health disparities must be carefully considered

Science 382:6676

Nevertheless, current evidence supports GLP-1 RAs and multi-agonist formulations as highly promising pharmacotherapies that address the complex, multifactorial pathophysiology of MASLD while simultaneously improving cardiometabolic comorbidities, positioning them as cornerstone treatments in the evolving therapeutic landscape for this prevalent and burdensome disease